A pharmacokinetic study of Neoral in childhood steroid-dependent nephrotic syndrome

Pediatr Nephrol. 2001 Feb;16(2):154-5. doi: 10.1007/s004670000520.


Seven children with steroid-dependent nephrotic syndrome who were on stable remission under Sandimmun therapy were switched to Neoral at the same dosage. During the 4-month follow-up period, two patients relapsed, due to poor compliance in one of them. Serum creatinine remained stable in all patients. Pharmacokinetic profiles were performed at day 0 while on Sandimmun and 4 weeks after conversion to Neoral. Following conversion to Neoral, the peak concentration occurred earlier (2+/-1.4 h vs 3.9+/-2.4 h), and the maximum concentration (677+/-386 ng/ml vs 488+/-265 ng/ml) and the area under the curve (3,082+/-1,536 ng/ml/h vs 2,201+/889 ng/ml/h) were higher. We conclude that Neoral results in an increased bioavailability of cyclosporine (CsA) as compared to Sandimmun in patients with steroid-dependent nephrotic syndrome in remission.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Anti-Inflammatory Agents / pharmacokinetics*
  • Anti-Inflammatory Agents / therapeutic use*
  • Area Under Curve
  • Child
  • Cyclosporine / pharmacokinetics*
  • Cyclosporine / therapeutic use*
  • Humans
  • Male
  • Nephrotic Syndrome / drug therapy*
  • Steroids


  • Anti-Inflammatory Agents
  • Steroids
  • Cyclosporine